{"gene":"IL6","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1992,"finding":"IL-6 receptor system consists of two membrane proteins: a ligand-binding chain (IL-6R) and a non-ligand-binding signal transducer gp130. Binding of IL-6 to IL-6R triggers the association of IL-6R and gp130, and gp130 transduces the signal. Despite lacking IL-6 binding property, gp130 is involved in the formation of high-affinity IL-6 binding sites.","method":"Receptor binding and signal transduction studies","journal":"International journal of immunopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — foundational receptor characterization replicated across multiple labs, mechanistic framework repeatedly confirmed","pmids":["1618596"],"is_preprint":false},{"year":1992,"finding":"NF-IL6 (C/EBP homolog) is a DNA-binding protein responsible for IL-1-stimulated IL-6 induction and is identical to IL-6DBP, the DNA-binding protein responsible for IL-6-mediated induction of acute-phase proteins. NF-IL6 binds to regulatory regions of the IL-6 gene and various other inducible genes involved in acute, immune, and inflammatory responses.","method":"Direct cloning, DNA binding assay, transcription factor identification","journal":"Immunological reviews","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct cloning with functional DNA binding validation, replicated across labs","pmids":["1380488"],"is_preprint":false},{"year":1999,"finding":"IL-6 type cytokine active signaling complexes with IL-6R and gp130 may exist as tetramers or hexamers; a model is proposed in which ligand-induced transition from an active tetrameric to an inactive hexameric complex serves as a molecular switch that turns off IL-6 signals at supraoptimal cytokine concentrations.","method":"Structural and biochemical analysis of receptor complex stoichiometry","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — structural/biochemical model from single lab, not independently replicated at time of publication","pmids":["10494829"],"is_preprint":false},{"year":2005,"finding":"IL-6 transsignaling: the IL-6/soluble IL-6 receptor (sIL-6R) complex acts as an agonist by binding to gp130 on cells that do not express membrane-bound IL-6R, thereby expanding IL-6 responsiveness. This trans-signaling is a crucial mechanism in chronic inflammatory diseases including inflammatory bowel disease, peritonitis, rheumatoid arthritis, and colon cancer.","method":"In vivo mouse models, recombinant protein studies, cell signaling assays","journal":"Journal of interferon & cytokine research","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple disease models and multiple labs, mechanistically defined with recombinant proteins","pmids":["15871661"],"is_preprint":false},{"year":2005,"finding":"IL-6 reduces the level of apoptosis among antigen-stimulated CD4 T cells (particularly those that have undergone five or more divisions) as shown by reduced annexin V staining, without affecting proliferative rates, thereby playing a central role in determining numbers of memory/effector CD4 T cells after immunization.","method":"CFSE dilution, BrdU labeling, annexin V staining in transgenic T cell transfer model, IL-6 KO mice","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (CFSE, BrdU, annexin V) with KO controls in single lab","pmids":["15814701"],"is_preprint":false},{"year":2002,"finding":"IL-6 promotes Th2 differentiation through activation of NFAT-mediated transcription leading to IL-4 production by naive CD4+ T cells, while simultaneously inhibiting Th1 differentiation through an IL-4- and NFAT-independent mechanism involving upregulation of SOCS-1 to interfere with IFNγ signaling.","method":"T cell differentiation assays, reporter assays, SOCS-1 expression analysis","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent molecular mechanisms identified with supporting functional assays, single lab","pmids":["12431386"],"is_preprint":false},{"year":2010,"finding":"IL-6, together with TGF-β, induces differentiation of Th17 cells from naive T cells, while IL-6 also inhibits TGF-β-induced regulatory T cell (Treg) differentiation, thereby regulating the Treg/Th17 balance.","method":"T cell differentiation assays, cytokine stimulation, KO mouse models","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic finding replicated across multiple labs with defined molecular pathway","pmids":["20583029"],"is_preprint":false},{"year":2014,"finding":"SOCS3 is the primary inhibitor of IL-6 signaling. Biochemical and structural studies show SOCS3 binds to gp130 and to JAK1, JAK2 and TYK2 (but not JAK3), with specificity determined by a three-residue 'GQM' motif in the kinase domain of JAK1, JAK2 and TYK2. SOCS3 binds JAK and gp130 simultaneously and inhibits JAK activity in an ATP-independent manner by partially occluding the substrate binding groove with its kinase inhibitory region.","method":"Biochemical binding assays, structural studies, mutagenesis of JAK kinase domain","journal":"Seminars in immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural and biochemical data with mutagenesis defining binding specificity, mechanistically rigorous","pmids":["24418198"],"is_preprint":false},{"year":2015,"finding":"Tet2 selectively mediates active repression of IL-6 transcription during inflammation resolution in innate myeloid cells. IκBζ mediates specific targeting of Tet2 to the Il6 promoter. Independent of DNA methylation and hydroxymethylation, Tet2 recruits Hdac2 and represses IL-6 transcription via histone deacetylation.","method":"Chromatin immunoprecipitation, Tet2-deficient mice, LPS challenge, gene-specific promoter analysis, histone modification assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods including ChIP, KO mice, reconstitution of repressor complex, published in high-tier journal","pmids":["26287468"],"is_preprint":false},{"year":2010,"finding":"IL-6 upregulates expression of RORγt (Th17-associated transcription factor) in NK cells and promotes IL-17 production. Only a subset of NK cells expresses both chains of the IL-6R. IL-6-deficient mice challenged with T. gondii had a major defect in NK cell production of IL-17.","method":"IL-6 KO mice, T. gondii infection model, flow cytometry, RORγt expression analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mice with defined cellular phenotype and molecular mechanism (RORγt upregulation), multiple orthogonal approaches","pmids":["20083665"],"is_preprint":false},{"year":2021,"finding":"IL-6 activates autophagy through the IL-6/JAK2/BECN1 pathway. IL-6 triggers the interaction between JAK2 and BECN1, where JAK2 phosphorylates BECN1 at Y333. BECN1 Y333 phosphorylation is crucial for BECN1 activation and IL-6-induced autophagy by regulating PI3KC3 complex formation, and promotes chemotherapy resistance in colorectal cancer.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (Y333), autophagy flux assays, cancer cell lines and in vivo models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted kinase-substrate interaction with mutagenesis validation, multiple orthogonal methods in single rigorous study","pmids":["34131122"],"is_preprint":false},{"year":2017,"finding":"IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 phosphorylation and STAT3 activation, which in turn increases RANKL expression at both mRNA and protein levels. Inhibition of JAK2 with AG490 suppressed phospho-JAK2 and RANKL expression and reduced osteoclastic differentiation.","method":"RT-PCR, Western blotting, TRAP staining, co-culture assay, JAK2 inhibitor AG490","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods including pharmacological inhibition and molecular analysis in osteocyte cell line, single lab","pmids":["28278513"],"is_preprint":false},{"year":2012,"finding":"c-Src stimulates IL-6 expression through STAT3, and IL-6 in turn induces IGFBP5 which activates c-Src, forming an amplification loop in immature osteoblasts. In mature osteoblasts this loop is broken because c-Src is downregulated. IGFBP5 produced by osteoblasts stimulates osteoclastogenesis, acting as an osteoblast-osteoclast coupling factor.","method":"In vitro and in vivo osteoblast differentiation assays, STAT3 reporter, siRNA knockdown, mouse models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — defined signaling loop with in vitro and in vivo validation, multiple orthogonal methods, single lab","pmids":["22252554"],"is_preprint":false},{"year":2005,"finding":"In neural stem cell differentiation, IL-6 family cytokines and BMPs act synergistically to induce astrocyte differentiation. This cooperation involves formation of a complex between STAT3 (downstream of IL-6 family cytokines) and Smad1 (downstream of BMPs), bridged by the transcriptional coactivator p300. A STAT3 binding element in the GFAP promoter is regulated by DNA methylation during brain development.","method":"Transcription factor complex analysis, promoter luciferase assays, DNA methylation analysis, neuroepithelial cell culture","journal":"Clinical reviews in allergy & immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined protein complex (STAT3-Smad1-p300) with functional promoter and methylation analysis, single lab","pmids":["16129909"],"is_preprint":false},{"year":2017,"finding":"Demethylase Kdm6a promotes IL-6 expression in macrophages through demethylating H3K27me3 at the IL-6 promoter in a demethylase enzymatic activity-dependent manner during innate immune responses.","method":"Chromatin immunoprecipitation, enzymatic activity-deficient mutants, primary macrophage knockdown, H3K27me3 histone modification assays","journal":"Journal of autoimmunity","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic activity mutagenesis with ChIP demonstrating direct epigenetic mechanism at IL-6 promoter, multiple orthogonal methods","pmids":["28284523"],"is_preprint":false},{"year":2014,"finding":"IL-6 stimulates intestinal epithelial proliferation and wound repair. Inhibition of IL-6 resulted in impaired wound healing due to decreased epithelial proliferation in two murine models of bowel injury (biopsy wound and bacterial-triggered colitis). IL-6 is induced after injury by multiple cell types including intraepithelial lymphocytes.","method":"Two murine bowel injury models, IL-6 inhibition, epithelial proliferation assays, human tissue analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent injury models with defined cellular phenotype (epithelial proliferation), single lab","pmids":["25478789"],"is_preprint":false},{"year":2017,"finding":"Autocrine IL-6 signaling in intestinal crypt epithelium regulates crypt homeostasis through Paneth cells via pSTAT3 activation and the Wnt signaling pathway. IL-6 receptor is restricted to the basal membrane of Paneth cells. IL-6-induced crypt organoid proliferation was abrogated by the Wnt inhibitor IWP2.","method":"Mouse intestinal crypt organoids, in vivo mouse model, IL-6R blocking antibody, Wnt inhibitor IWP2, immunolabeling, IL-6 neutralizing antibody","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway defined with pathway inhibitors and both in vitro organoid and in vivo systems, multiple orthogonal methods","pmids":["28550196"],"is_preprint":false},{"year":2023,"finding":"Post-myocardial infarction IL-6 is preferentially produced by cardiac fibroblasts (CFs). Adenosine stimulates fibroblast IL-6 formation via the adenosine receptor A2bR in a Gq-dependent manner. T cell-derived adenosine (from CD73 on T cells) modulates IL-6 formation in CFs, representing purinergic metabolic cooperation between CFs and T cells.","method":"Single-cell RNA-seq (mouse and human hearts), quantitative PCR, RNAscope, protein-level cell-type analysis, genetic mouse models (CD4-CD73-/-), in vitro receptor pharmacology","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — scRNA-seq confirmed in human and mouse tissue, defined receptor (A2bR/Gq) and genetic KO validation, multiple orthogonal methods","pmids":["36943408"],"is_preprint":false},{"year":2013,"finding":"IL-6 functions downstream of IL-17A to exacerbate neutrophil microabscess development in psoriasiform skin lesions. IL-17A expression results in upregulated granulopoiesis and migration of IL-6R-expressing neutrophils into the skin. Neutralization of IL-6 signaling efficiently reduced epidermal neutrophil abscess formation and epidermal thickening.","method":"Transgenic IL-17A skin mouse model, IL-6 neutralization, histopathology, granulopoiesis analysis","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis defined with transgenic model and antibody neutralization, single lab","pmids":["24067382"],"is_preprint":false},{"year":2023,"finding":"IL-6 signaling in Tet2-deficient macrophages induces Csf1r expression through enhanced STAT3 binding to the CSF1R promoter, increasing macrophage survival and contributing to accelerated atherosclerosis in clonal hematopoiesis. IL-6 receptor antibody treatment reverses Tet2-deficient clonal hematopoiesis-promoted atherosclerosis.","method":"ChIP for STAT3 at Csf1r promoter, mouse and human Tet2-deficient macrophages, IL-6R antibody treatment, CSF1R inhibitor PLX3397, atherosclerosis mouse model","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP defines direct STAT3-mediated mechanism, validated in both mouse and human cells with pharmacological rescue, multiple orthogonal approaches","pmids":["37539077"],"is_preprint":false},{"year":2023,"finding":"Phase separation of the YY1 complex in M2 macrophages upregulates IL-6 by promoting IL-6 enhancer-promoter interactions via long-range chromatin interaction. An M2-specific IL-6 enhancer was identified; YY1 formed a liquid-liquid phase separation in which p300, p65, and CEBPB acted as transcriptional cofactors to drive IL-6 expression.","method":"H3K27ac-ChIP-seq, YY1 ChIP-seq, CRISPR-Cas9 knockout, RNA-seq, liquid-liquid phase separation assays, chromatin interaction analysis","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods including ChIP-seq, LLPS assays, CRISPR KO, and long-range chromatin interaction analysis in single rigorous study","pmids":["37094986"],"is_preprint":false},{"year":2021,"finding":"IL-6 signaling in macrophages is critical for immunotherapy-driven tumor regression. IL-6 receptor signaling in macrophages is required for effective M1-type macrophage function; IL-6 signaling blockade decreased SOCS3 expression in macrophages and increased expression of the phagocytic checkpoint molecule SIRPα. Macrophage-specific IL-6R deletion (Il6rafl/fl×LysMcre+) impaired therapy efficacy without affecting vaccine-induced CD8+ T cell responses.","method":"Macrophage-specific conditional IL-6R knockout mice, therapeutic vaccination tumor model, flow cytometry, SOCS3 and SIRPα expression analysis","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with defined molecular mechanism (SOCS3, SIRPα), multiple orthogonal methods","pmids":["33879600"],"is_preprint":false},{"year":2021,"finding":"IL-6 upregulates CCR5 expression and arginase 1 in MDSC through a STAT3-dependent mechanism, enhancing their immunosuppressive capacity. MDSC differentiated in the presence of IL-6 strongly inhibited CD8+ T cell functions compared with MDSC differentiated without IL-6. Correlation between IL-6 levels, phosphorylated STAT3, and CCR5 expression was demonstrated in tumor-infiltrating MDSC in a transgenic melanoma model.","method":"In vitro MDSC differentiation, STAT3 phosphorylation analysis, mRNA/protein expression, RET transgenic melanoma mouse model, CD8+ T cell suppression assay","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined STAT3-dependent mechanism with in vitro and in vivo validation, single lab","pmids":["32788238"],"is_preprint":false},{"year":2016,"finding":"IL-6 treatment of myotubes increases fatty acid oxidation, basal and insulin-stimulated glucose uptake, and translocation of GLUT4 to the plasma membrane. IL-6 rapidly and markedly increases AMPK activity, and the metabolic effects of IL-6 were abrogated in AMPK dominant-negative infected cells.","method":"Myotube cell culture, fatty acid oxidation assay, glucose uptake assay, GLUT4 translocation assay, AMPK dominant-negative expression","journal":"Biochemical Society transactions","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — AMPK dominant-negative establishes mechanistic requirement, multiple metabolic readouts, single lab","pmids":["17956334"],"is_preprint":false},{"year":2014,"finding":"IL-6 inhibits allograft acceptance by promoting T cell alloimmune responses and impairing the ability of regulatory T cells to suppress effector T cell alloimmunity. Absence of both IL-6 and TNF-α in the graft recipient synergized with co-stimulatory blockade to induce tolerance.","method":"Murine skin allograft model, IL-6/TNF-α double KO, co-stimulatory blockade, in vitro and in vivo T cell assays","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO combined with transplant model defines synergistic mechanism, single lab","pmids":["19357252"],"is_preprint":false},{"year":2011,"finding":"CK2 (protein kinase CK2) regulates IL-6 expression in inflammatory breast cancer. siRNA knockdown of CK2 and the selective CK2 inhibitor CX-4945 suppressed IL-6 expression and secretion in vitro and in vivo. CK2 inhibition also reduced plasma IL-6 levels in a clinical trial patient.","method":"siRNA knockdown, small molecule inhibitor (CX-4945), ELISA, in vitro and in vivo cancer models, clinical sample analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — convergent siRNA and pharmacological evidence, but single lab with limited mechanistic detail on direct vs indirect CK2 action","pmids":["22027148"],"is_preprint":false},{"year":2014,"finding":"The BET bromodomain protein inhibitor I-BET151 selectively inhibits IL-6 production (but not TNFα, IL-1β, or IL-10) in LPS-stimulated macrophages by preventing the binding of CBP to the IL-6 promoter, without affecting NF-κB acetylation, phosphorylation, nuclear translocation, or DNA binding.","method":"Chromatin immunoprecipitation (CBP binding at IL-6 promoter), cytokine ELISA, NF-κB activity assays, LPS-stimulated RAW264.7 cells","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP defines direct CBP recruitment mechanism with selectivity demonstrated by parallel cytokine measurements, single lab","pmids":["24859008"],"is_preprint":false},{"year":2015,"finding":"IL-6 trans-signaling via soluble IL-6R drives crescentic nephritis. Specific inhibition of IL-6 trans-signaling using recombinant sgp130Fc resulted in milder nephritis, while specific activation using a recombinant IL-6-sIL-6R fusion molecule (Hyper-IL-6) significantly aggravated disease and increased systolic BP. Simultaneous inhibition of both IL-6 signaling pathways using anti-IL-6 antibody alone had no significant impact.","method":"Nephrotoxic serum-induced nephritis mouse model, recombinant sgp130Fc (trans-signaling specific inhibitor), Hyper-IL-6 fusion protein, pSTAT3/SOCS3 analysis, Th17 cytokine measurement","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pathway-specific inhibition and activation with recombinant proteins establishes trans-signaling mechanism, multiple readouts, single lab","pmids":["26041841"],"is_preprint":false},{"year":2017,"finding":"Autocrine IL-6 maintains cellular senescence in pituitary somatotroph tumor cells. Endogenous IL-6 inhibition via shRNA in MtT/S clones decreased SA-β-gal activity and p16INK4a but increased pRb and proliferation/invasion. IL-6-silenced clones became tumorigenic in nude mice, while wild-type MtT/S cells did not, demonstrating that escape from IL-6-driven senescence enables malignant transformation.","method":"shRNA stable knockdown, SA-β-gal staining, p16INK4a/pRb Western blot, nude mouse xenograft, human pituitary tumor samples","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA KD with in vitro and in vivo phenotypic validation including senescence markers, single lab","pmids":["27902467"],"is_preprint":false},{"year":2020,"finding":"In human astrocytes, β-catenin in complex with TCF/LEF inhibits IL-6 transcription, while TCF/LEF independent of β-catenin induces IL-6 transcription through interaction with ATF-2/SMADs. β-catenin independent of TCFs/LEF positively regulates C/EBP and NF-κB to activate IL-6 expression. Two TCF/LEF binding sites in the IL-6 promoter were identified (at -91 nt and -948 nt from TSS), both required for TCF/LEF induction of IL-6.","method":"siRNA knockdown, cDNA overexpression, IL-6 promoter luciferase reporter, site-directed mutagenesis of promoter sites, chromatin immunoprecipitation, pharmacological agents","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis and ChIP define binding sites, multiple complementary approaches, single lab","pmids":["32546183"],"is_preprint":false},{"year":2004,"finding":"IL-6 strongly increases CD44 gene expression in multiple myeloma cells, modulates CD44 RNA alternative splicing inducing overexpression of all CD44 variant exons, and induces a functional polarized membrane distribution of CD44 cell surface molecules.","method":"RT-PCR, Western blot, flow cytometry, cell surface distribution analysis in myeloma cell lines","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple molecular readouts (mRNA splicing, protein expression, surface distribution) in cell lines, single lab","pmids":["15014527"],"is_preprint":false}],"current_model":"IL-6 is a pleiotropic cytokine that signals through a receptor complex comprising IL-6R and gp130: binding of IL-6 to IL-6R triggers association with gp130, which dimerizes and initiates intracellular JAK-STAT3, Ras-MAPK, and PI3K-Akt signaling; trans-signaling extends this response to cells lacking membrane IL-6R by using soluble IL-6R complexed with gp130; SOCS3 terminates signaling by simultaneously binding gp130 and JAK1/2/TYK2 to occlude the kinase substrate groove; at the transcriptional level, IL-6 gene expression is regulated by NF-IL6/C/EBP, NF-κB, STAT3, and epigenetic mechanisms including Tet2-Hdac2-mediated histone deacetylation for resolution-phase repression, Kdm6a-mediated H3K27 demethylation for induction, and YY1 phase-separation complexes at enhancers; downstream, IL-6 controls immune cell fate (Th17/Treg balance, CD4 T cell survival, NK cell IL-17 production), metabolic responses (AMPK activation, GLUT4 translocation), cellular senescence (autocrine loop in pituitary adenomas), autophagy (via JAK2 phosphorylation of BECN1 at Y333), and tissue homeostasis (intestinal crypt Paneth cell-Wnt axis), with post-MI IL-6 production being predominantly driven by cardiac fibroblasts via adenosine/A2bR/Gq signaling."},"narrative":{"mechanistic_narrative":"IL-6 is a pleiotropic secreted cytokine that orchestrates immune cell fate, tissue repair, and metabolic responses by signaling through a two-chain receptor system in which a ligand-binding chain (IL-6R) captures IL-6 and triggers association with the signal-transducing chain gp130, the latter forming high-affinity binding sites and transducing the intracellular signal [PMID:1618596]. The active signaling complex assembles into higher-order tetrameric/hexameric stoichiometries, and a ligand-induced transition to an inactive hexamer can act as a switch that limits signaling at supraoptimal cytokine concentrations [PMID:10494829]. IL-6 also acts via trans-signaling, in which the IL-6/soluble IL-6R complex agonizes gp130 on cells lacking membrane IL-6R, a mechanism that drives chronic inflammatory disease including bowel inflammation, rheumatoid arthritis, and crescentic nephritis [PMID:15871661, PMID:26041841]. Downstream, IL-6 engages a JAK2-STAT3 axis that phosphorylates STAT3 to control target gene transcription — driving RANKL for osteoclastogenesis [PMID:28278513], CSF1R for macrophage survival [PMID:37539077], and immunosuppressive programs (CCR5/arginase-1) in MDSC [PMID:32788238] — and JAK2 also phosphorylates BECN1 at Y333 to activate PI3KC3-dependent autophagy [PMID:34131122]. The cytokine is a central determinant of T cell fate, cooperating with TGF-β to induce Th17 differentiation while suppressing Treg differentiation [PMID:20583029], reducing apoptosis of antigen-stimulated CD4 T cells [PMID:15814701], and inducing IL-17 production in NK cells via RORγt [PMID:20083665]. Beyond immunity, IL-6 promotes intestinal epithelial proliferation and crypt homeostasis through a Paneth cell pSTAT3-Wnt axis [PMID:28550196], activates AMPK to stimulate fatty acid oxidation and GLUT4-mediated glucose uptake in muscle [PMID:17956334], and sustains autocrine senescence in pituitary tumor cells [PMID:27902467]. Signaling is terminated by SOCS3, which binds gp130 and JAK1/JAK2/TYK2 simultaneously (via a GQM motif in the kinase domain) and occludes the substrate groove in an ATP-independent manner [PMID:24418198]. IL-6 transcription itself is tightly controlled by transcription factors NF-IL6/C/EBP, NF-κB, and STAT3 together with epigenetic machinery, including Tet2-Hdac2-mediated histone deacetylation for resolution-phase repression [PMID:26287468], Kdm6a-mediated H3K27 demethylation for induction [PMID:28284523], and YY1 phase-separation enhancer complexes [PMID:37094986].","teleology":[{"year":1992,"claim":"Established the architecture of IL-6 reception by resolving that ligand binding and signal transduction are split between two membrane chains, defining how IL-6 can be sensed and propagated.","evidence":"Receptor binding and signal transduction studies of IL-6R and gp130","pmids":["1618596"],"confidence":"High","gaps":["Stoichiometry of the active complex not resolved here","Intracellular effectors of gp130 not yet defined"]},{"year":1992,"claim":"Identified NF-IL6/C/EBP as the DNA-binding factor coupling inflammatory stimuli to IL-6 gene induction, linking IL-6 transcription to the acute-phase response.","evidence":"Direct cloning and DNA-binding assays identifying NF-IL6 at IL-6 regulatory regions","pmids":["1380488"],"confidence":"High","gaps":["Combinatorial control with other factors not defined","No chromatin-level mechanism established"]},{"year":1999,"claim":"Proposed that receptor complex stoichiometry (tetramer-to-hexamer transition) functions as a built-in molecular switch limiting signaling at high ligand, addressing how IL-6 responses are self-limited.","evidence":"Structural and biochemical analysis of IL-6/IL-6R/gp130 complex stoichiometry","pmids":["10494829"],"confidence":"Medium","gaps":["Single-lab structural model not independently replicated at publication","Physiological relevance of the switch in vivo unresolved"]},{"year":2005,"claim":"Defined IL-6 trans-signaling, showing the soluble IL-6R/IL-6 complex extends responsiveness to gp130-bearing cells lacking IL-6R, explaining IL-6's role in chronic inflammation.","evidence":"In vivo mouse disease models and recombinant protein signaling assays","pmids":["15871661"],"confidence":"High","gaps":["Cellular source of sIL-6R per tissue not fully mapped","Relative contribution of classic vs trans-signaling per disease unclear"]},{"year":2005,"claim":"Showed IL-6 shapes adaptive immunity by reducing apoptosis of divided antigen-stimulated CD4 T cells, establishing its role in memory/effector T cell accumulation.","evidence":"CFSE/BrdU/annexin V assays in transgenic T cell transfer and IL-6 KO mice","pmids":["15814701"],"confidence":"High","gaps":["Downstream survival effectors not identified","Single-lab finding"]},{"year":2010,"claim":"Placed IL-6 at the center of the Treg/Th17 decision, demonstrating it cooperates with TGF-β to drive Th17 while blocking Treg differentiation, and extends Th17-like programs to NK cells.","evidence":"T cell differentiation assays and KO mice; RORγt analysis in NK cells in T. gondii infection","pmids":["20583029","20083665"],"confidence":"High","gaps":["Transcriptional logic of the Treg/Th17 switch not fully detailed","NK IL-6R expression heterogeneity not explained"]},{"year":2014,"claim":"Resolved the structural basis of IL-6 signal termination, showing SOCS3 simultaneously engages gp130 and specific JAKs to occlude the kinase substrate groove.","evidence":"Biochemical binding, structural studies, and mutagenesis of the JAK GQM motif","pmids":["24418198"],"confidence":"High","gaps":["Kinetics of SOCS3 induction vs signaling not quantified","JAK3 exclusion mechanism beyond GQM not addressed"]},{"year":2015,"claim":"Connected IL-6 gene control to active epigenetic repression, showing Tet2 (targeted by IκBζ) recruits Hdac2 to deacetylate the Il6 promoter independently of DNA methylation during inflammation resolution.","evidence":"ChIP, Tet2-deficient mice, LPS challenge, histone modification assays","pmids":["26287468"],"confidence":"High","gaps":["Signals triggering resolution-phase Tet2 recruitment not fully defined","Generalizability beyond myeloid cells unclear"]},{"year":2017,"claim":"Identified the opposing inductive epigenetic arm, with Kdm6a demethylating H3K27me3 at the IL-6 promoter to permit expression during innate responses.","evidence":"ChIP, enzymatic-dead mutants, and primary macrophage knockdown","pmids":["28284523"],"confidence":"High","gaps":["Upstream signals recruiting Kdm6a not defined","Interplay with Tet2-Hdac2 repression not mapped"]},{"year":2017,"claim":"Linked IL-6/JAK2/STAT3 signaling to bone remodeling, showing it raises RANKL to enhance osteocyte-mediated osteoclastogenesis.","evidence":"RT-PCR, Western blot, TRAP staining, co-culture, and JAK2 inhibition (AG490)","pmids":["28278513"],"confidence":"Medium","gaps":["Direct vs indirect STAT3 control of RANKL promoter not resolved","Single cell-line system"]},{"year":2021,"claim":"Expanded IL-6's intracellular reach to autophagy, demonstrating JAK2 phosphorylates BECN1 at Y333 to drive PI3KC3 complex formation and chemoresistance.","evidence":"Co-IP, in vitro kinase assay, Y333 mutagenesis, autophagy flux, and cancer models","pmids":["34131122"],"confidence":"High","gaps":["Receptor-proximal coupling to cytosolic JAK2-BECN1 not fully mapped","Generalizability beyond colorectal cancer unclear"]},{"year":2021,"claim":"Showed IL-6 metabolically reprograms muscle, rapidly activating AMPK to drive fatty acid oxidation and GLUT4-dependent glucose uptake.","evidence":"Myotube metabolic assays with AMPK dominant-negative expression","pmids":["17956334"],"confidence":"Medium","gaps":["Receptor route (classic vs trans) in myotubes not specified","Single-lab finding"]},{"year":2023,"claim":"Defined the cellular source and induction of IL-6 in injured heart, showing cardiac fibroblasts produce IL-6 via adenosine/A2bR/Gq signaling fed by T cell-derived adenosine.","evidence":"scRNA-seq (mouse and human), RNAscope, CD4-CD73 KO mice, receptor pharmacology","pmids":["36943408"],"confidence":"High","gaps":["Downstream cardiac consequences of fibroblast IL-6 not detailed here","Translation to human cardiac outcomes pending"]},{"year":2023,"claim":"Revealed enhancer-level control of IL-6 in tumor-associated macrophages, with YY1 liquid-liquid phase separation organizing p300/p65/CEBPB to drive M2-specific enhancer-promoter looping.","evidence":"H3K27ac/YY1 ChIP-seq, CRISPR KO, LLPS assays, chromatin interaction analysis","pmids":["37094986"],"confidence":"High","gaps":["Triggers of YY1 condensate formation not defined","Relationship to NF-IL6/STAT3 promoter control unresolved"]},{"year":null,"claim":"How the receptor-proximal JAK-STAT3 module is integrated with the diverse downstream effectors (autophagy, AMPK metabolism, senescence) and the multilayered transcriptional/epigenetic control of the IL-6 gene into a unified, context-dependent response remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No single framework reconciles classic vs trans-signaling outputs across tissues","Quantitative integration of activating (Kdm6a, YY1) and repressive (Tet2-Hdac2) IL-6 transcription not established","Structural basis of the proposed hexamer off-switch in vivo not confirmed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,3]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,17]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,7]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,6,9]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,14,20]}],"complexes":["IL-6/IL-6R/gp130 signaling complex"],"partners":["IL6R","IL6ST","SOCS3","JAK2","STAT3","BECN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05231","full_name":"Interleukin-6","aliases":["B-cell stimulatory factor 2","BSF-2","CTL differentiation factor","CDF","Hybridoma growth factor","Interferon beta-2","IFN-beta-2"],"length_aa":212,"mass_kda":23.7,"function":"Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable) IL6 is a potent inducer of the acute phase response. Rapid production of IL6 contributes to host defense during infection and tissue injury, but excessive IL6 synthesis is involved in disease pathology. In the innate immune response, is synthesized by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (Probable). In the adaptive immune response, is required for the differentiation of B cells into immunoglobulin-secreting cells. Plays a major role in the differentiation of CD4(+) T cell subsets. Essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-center formation. Required to drive naive CD4(+) T cells to the Th17 lineage. Also required for proliferation of myeloma cells and the survival of plasmablast cells (By similarity) Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability (PubMed:12794819, PubMed:17075861). Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF (PubMed:12794819). Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance (PubMed:20823453). 'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis (By similarity). Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand (By similarity). Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity). Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection (PubMed:15124018). Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P05231/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL6","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL6","total_profiled":1310},"omim":[{"mim_id":"621409","title":"AUTOINFLAMMATION AND AUTOIMMUNITY, SYSTEMIC, WITH IMMUNE DYSREGULATION 2; AIAISD2","url":"https://www.omim.org/entry/621409"},{"mim_id":"621401","title":"DEAH-BOX HELICASE 35; DHX35","url":"https://www.omim.org/entry/621401"},{"mim_id":"621142","title":"CHROMOSOME 15 OPEN READING FRAME 39; C15ORF39","url":"https://www.omim.org/entry/621142"},{"mim_id":"621096","title":"IMMUNODEFICIENCY 132B; IMD132B","url":"https://www.omim.org/entry/621096"},{"mim_id":"621030","title":"AUTOINFLAMMATION, PANNICULITIS, AND DERMATOSIS SYNDROME, AUTOSOMAL DOMINANT; AIPDSA","url":"https://www.omim.org/entry/621030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":187.7},{"tissue":"lung","ntpm":140.6},{"tissue":"urinary bladder","ntpm":256.4}],"url":"https://www.proteinatlas.org/search/IL6"},"hgnc":{"alias_symbol":["IL-6","BSF2","HGF","HSF"],"prev_symbol":["IFNB2"]},"alphafold":{"accession":"P05231","domains":[{"cath_id":"1.20.1250.10","chopping":"48-209","consensus_level":"high","plddt":93.0108,"start":48,"end":209}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05231","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05231-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05231-F1-predicted_aligned_error_v6.png","plddt_mean":85.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL6","jax_strain_url":"https://www.jax.org/strain/search?query=IL6"},"sequence":{"accession":"P05231","fasta_url":"https://rest.uniprot.org/uniprotkb/P05231.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05231/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05231"}},"corpus_meta":[{"pmid":"25190079","id":"PMC_25190079","title":"IL-6 in inflammation, immunity, and disease.","date":"2014","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/25190079","citation_count":3657,"is_preprint":false},{"pmid":"25898198","id":"PMC_25898198","title":"IL-6 as a keystone cytokine in health and disease.","date":"2015","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25898198","citation_count":1901,"is_preprint":false},{"pmid":"20583029","id":"PMC_20583029","title":"IL-6: regulator of Treg/Th17 balance.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20583029","citation_count":1292,"is_preprint":false},{"pmid":"26867490","id":"PMC_26867490","title":"IL-6 pathway in the liver: From physiopathology to therapy.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26867490","citation_count":714,"is_preprint":false},{"pmid":"12431386","id":"PMC_12431386","title":"The two faces of IL-6 on Th1/Th2 differentiation.","date":"2002","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12431386","citation_count":696,"is_preprint":false},{"pmid":"26287468","id":"PMC_26287468","title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26287468","citation_count":680,"is_preprint":false},{"pmid":"20410258","id":"PMC_20410258","title":"IL-6: from its discovery to clinical applications.","date":"2010","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20410258","citation_count":617,"is_preprint":false},{"pmid":"29499302","id":"PMC_29499302","title":"Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters.","date":"2018","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29499302","citation_count":598,"is_preprint":false},{"pmid":"24602448","id":"PMC_24602448","title":"The two faces of IL-6 in the tumor microenvironment.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24602448","citation_count":566,"is_preprint":false},{"pmid":"27381687","id":"PMC_27381687","title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm.","date":"2016","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/27381687","citation_count":498,"is_preprint":false},{"pmid":"32327746","id":"PMC_32327746","title":"Translating IL-6 biology into effective treatments.","date":"2020","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/32327746","citation_count":495,"is_preprint":false},{"pmid":"1380488","id":"PMC_1380488","title":"IL-6 and NF-IL6 in acute-phase response and viral infection.","date":"1992","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/1380488","citation_count":472,"is_preprint":false},{"pmid":"14609022","id":"PMC_14609022","title":"Searching for the exercise factor: is IL-6 a candidate?","date":"2003","source":"Journal of muscle research and cell motility","url":"https://pubmed.ncbi.nlm.nih.gov/14609022","citation_count":396,"is_preprint":false},{"pmid":"12110143","id":"PMC_12110143","title":"The paradigm of IL-6: from basic science to medicine.","date":"2002","source":"Arthritis research","url":"https://pubmed.ncbi.nlm.nih.gov/12110143","citation_count":368,"is_preprint":false},{"pmid":"31992476","id":"PMC_31992476","title":"A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.","date":"2020","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31992476","citation_count":341,"is_preprint":false},{"pmid":"25616716","id":"PMC_25616716","title":"Versatile functions for IL-6 in metabolism and cancer.","date":"2015","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25616716","citation_count":301,"is_preprint":false},{"pmid":"28778870","id":"PMC_28778870","title":"Interleukin (IL-6) Immunotherapy.","date":"2018","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/28778870","citation_count":300,"is_preprint":false},{"pmid":"23532539","id":"PMC_23532539","title":"The role of intratumoral and systemic IL-6 in breast cancer.","date":"2013","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/23532539","citation_count":289,"is_preprint":false},{"pmid":"25649043","id":"PMC_25649043","title":"The varying faces of IL-6: From cardiac protection to cardiac failure.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/25649043","citation_count":268,"is_preprint":false},{"pmid":"25136784","id":"PMC_25136784","title":"IL-6 biology: implications for clinical targeting in rheumatic disease.","date":"2014","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/25136784","citation_count":242,"is_preprint":false},{"pmid":"30584363","id":"PMC_30584363","title":"IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis.","date":"2018","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30584363","citation_count":230,"is_preprint":false},{"pmid":"25478789","id":"PMC_25478789","title":"IL-6 stimulates intestinal epithelial proliferation and repair after injury.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25478789","citation_count":219,"is_preprint":false},{"pmid":"15871661","id":"PMC_15871661","title":"IL-6 transsignaling: the in vivo consequences.","date":"2005","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/15871661","citation_count":208,"is_preprint":false},{"pmid":"34131122","id":"PMC_34131122","title":"IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34131122","citation_count":205,"is_preprint":false},{"pmid":"28278513","id":"PMC_28278513","title":"IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28278513","citation_count":202,"is_preprint":false},{"pmid":"27330885","id":"PMC_27330885","title":"Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6.","date":"2016","source":"SpringerPlus","url":"https://pubmed.ncbi.nlm.nih.gov/27330885","citation_count":191,"is_preprint":false},{"pmid":"20083665","id":"PMC_20083665","title":"IL-6 promotes NK cell production of IL-17 during toxoplasmosis.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20083665","citation_count":176,"is_preprint":false},{"pmid":"24418198","id":"PMC_24418198","title":"Inhibition of IL-6 family cytokines by SOCS3.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24418198","citation_count":170,"is_preprint":false},{"pmid":"27734409","id":"PMC_27734409","title":"Regulation of IL-6 in Immunity and Diseases.","date":"2016","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/27734409","citation_count":168,"is_preprint":false},{"pmid":"1918953","id":"PMC_1918953","title":"Regulation of IL-6 expression by oncostatin M.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1918953","citation_count":154,"is_preprint":false},{"pmid":"22652781","id":"PMC_22652781","title":"IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?","date":"2012","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/22652781","citation_count":142,"is_preprint":false},{"pmid":"34711820","id":"PMC_34711820","title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34711820","citation_count":128,"is_preprint":false},{"pmid":"17956334","id":"PMC_17956334","title":"IL-6 signalling in exercise and disease.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17956334","citation_count":127,"is_preprint":false},{"pmid":"37633799","id":"PMC_37633799","title":"The exercise IL-6 enigma in cancer.","date":"2023","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/37633799","citation_count":114,"is_preprint":false},{"pmid":"37094986","id":"PMC_37094986","title":"YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37094986","citation_count":111,"is_preprint":false},{"pmid":"25031389","id":"PMC_25031389","title":"Gene of the month: Interleukin 6 (IL-6).","date":"2014","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25031389","citation_count":111,"is_preprint":false},{"pmid":"23994594","id":"PMC_23994594","title":"Brain IL-6 and autism.","date":"2013","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23994594","citation_count":109,"is_preprint":false},{"pmid":"28507168","id":"PMC_28507168","title":"Nutritional interventions and the IL-6 response to exercise.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28507168","citation_count":109,"is_preprint":false},{"pmid":"32788238","id":"PMC_32788238","title":"IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32788238","citation_count":108,"is_preprint":false},{"pmid":"15814701","id":"PMC_15814701","title":"IL-6 increases primed cell expansion and survival.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15814701","citation_count":106,"is_preprint":false},{"pmid":"10494829","id":"PMC_10494829","title":"IL-6 type cytokine receptor complexes: hexamer, tetramer or both?","date":"1999","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10494829","citation_count":104,"is_preprint":false},{"pmid":"35924148","id":"PMC_35924148","title":"IL-6: The Link Between Inflammation, Immunity and Breast Cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35924148","citation_count":102,"is_preprint":false},{"pmid":"22252554","id":"PMC_22252554","title":"c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling.","date":"2012","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/22252554","citation_count":100,"is_preprint":false},{"pmid":"28363692","id":"PMC_28363692","title":"IL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives.","date":"2017","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28363692","citation_count":98,"is_preprint":false},{"pmid":"19365268","id":"PMC_19365268","title":"Clinical value of blocking IL-6 receptor.","date":"2009","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19365268","citation_count":97,"is_preprint":false},{"pmid":"30248523","id":"PMC_30248523","title":"IL-6: a cytokine at the crossroads of autoimmunity.","date":"2018","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30248523","citation_count":96,"is_preprint":false},{"pmid":"24067382","id":"PMC_24067382","title":"IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions.","date":"2013","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24067382","citation_count":96,"is_preprint":false},{"pmid":"28550196","id":"PMC_28550196","title":"IL-6 Signaling Regulates Small Intestinal Crypt Homeostasis.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28550196","citation_count":92,"is_preprint":false},{"pmid":"16129909","id":"PMC_16129909","title":"Role of IL-6 in the neural stem cell differentiation.","date":"2005","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16129909","citation_count":91,"is_preprint":false},{"pmid":"34405445","id":"PMC_34405445","title":"Role of IL-6 in dendritic cell functions.","date":"2021","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/34405445","citation_count":85,"is_preprint":false},{"pmid":"24613573","id":"PMC_24613573","title":"The IL-6 feed-forward loop: a driver of tumorigenesis.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24613573","citation_count":85,"is_preprint":false},{"pmid":"31592285","id":"PMC_31592285","title":"IL-6 Activities in the Tumour Microenvironment. Part 1.","date":"2019","source":"Open access Macedonian journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31592285","citation_count":84,"is_preprint":false},{"pmid":"19357252","id":"PMC_19357252","title":"IL-6 and TNF-alpha synergistically inhibit allograft acceptance.","date":"2009","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19357252","citation_count":82,"is_preprint":false},{"pmid":"29336982","id":"PMC_29336982","title":"IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice.","date":"2018","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/29336982","citation_count":80,"is_preprint":false},{"pmid":"20148256","id":"PMC_20148256","title":"Involvement of IL-17F via the induction of IL-6 in psoriasis.","date":"2010","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/20148256","citation_count":75,"is_preprint":false},{"pmid":"28284523","id":"PMC_28284523","title":"Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28284523","citation_count":73,"is_preprint":false},{"pmid":"30135299","id":"PMC_30135299","title":"IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30135299","citation_count":71,"is_preprint":false},{"pmid":"21054880","id":"PMC_21054880","title":"Palmitate and insulin synergistically induce IL-6 expression in human monocytes.","date":"2010","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/21054880","citation_count":70,"is_preprint":false},{"pmid":"39589436","id":"PMC_39589436","title":"IL-6 and Cardiovascular Risk: A Narrative Review.","date":"2024","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/39589436","citation_count":68,"is_preprint":false},{"pmid":"27082319","id":"PMC_27082319","title":"Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes.","date":"2016","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/27082319","citation_count":67,"is_preprint":false},{"pmid":"1618596","id":"PMC_1618596","title":"IL-6 receptor and mechanism of signal transduction.","date":"1992","source":"International journal of immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/1618596","citation_count":65,"is_preprint":false},{"pmid":"24633552","id":"PMC_24633552","title":"IL-6 regulates adipose deposition and homeostasis in lymphedema.","date":"2014","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24633552","citation_count":63,"is_preprint":false},{"pmid":"37539077","id":"PMC_37539077","title":"Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis.","date":"2023","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/37539077","citation_count":61,"is_preprint":false},{"pmid":"35340805","id":"PMC_35340805","title":"Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35340805","citation_count":61,"is_preprint":false},{"pmid":"22027148","id":"PMC_22027148","title":"Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22027148","citation_count":60,"is_preprint":false},{"pmid":"27876525","id":"PMC_27876525","title":"IL-6 roles - Molecular pathway and clinical implication in pancreatic cancer - A systemic review.","date":"2016","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27876525","citation_count":59,"is_preprint":false},{"pmid":"34099967","id":"PMC_34099967","title":"IL-6 Directed Therapy in Transplantation.","date":"2021","source":"Current transplantation reports","url":"https://pubmed.ncbi.nlm.nih.gov/34099967","citation_count":57,"is_preprint":false},{"pmid":"25547486","id":"PMC_25547486","title":"Upregulation of TLRs and IL-6 as a marker in human colorectal cancer.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25547486","citation_count":57,"is_preprint":false},{"pmid":"16129902","id":"PMC_16129902","title":"IL-6: from laboratory to bedside.","date":"2005","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16129902","citation_count":55,"is_preprint":false},{"pmid":"25627031","id":"PMC_25627031","title":"IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis.","date":"2015","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/25627031","citation_count":55,"is_preprint":false},{"pmid":"21427577","id":"PMC_21427577","title":"The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.","date":"2011","source":"Current opinion in rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/21427577","citation_count":55,"is_preprint":false},{"pmid":"36943408","id":"PMC_36943408","title":"IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36943408","citation_count":54,"is_preprint":false},{"pmid":"17384473","id":"PMC_17384473","title":"Essential role of IL-6 signaling pathway in keloid pathogenesis.","date":"2007","source":"Journal of Nippon Medical School = Nippon Ika Daigaku zasshi","url":"https://pubmed.ncbi.nlm.nih.gov/17384473","citation_count":53,"is_preprint":false},{"pmid":"29276788","id":"PMC_29276788","title":"A Role for Soluble IL-6 Receptor in Osteoarthritis.","date":"2017","source":"Journal of functional morphology and kinesiology","url":"https://pubmed.ncbi.nlm.nih.gov/29276788","citation_count":53,"is_preprint":false},{"pmid":"27497026","id":"PMC_27497026","title":"Revisiting IL-6 antagonism in multiple myeloma.","date":"2016","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/27497026","citation_count":48,"is_preprint":false},{"pmid":"35527168","id":"PMC_35527168","title":"IL-6 and its role in IgA nephropathy development.","date":"2022","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35527168","citation_count":47,"is_preprint":false},{"pmid":"14561164","id":"PMC_14561164","title":"IL-6 and Crohn's disease.","date":"2003","source":"Current drug targets. Inflammation and allergy","url":"https://pubmed.ncbi.nlm.nih.gov/14561164","citation_count":47,"is_preprint":false},{"pmid":"26041841","id":"PMC_26041841","title":"IL-6 Trans-Signaling Drives Murine Crescentic GN.","date":"2015","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/26041841","citation_count":47,"is_preprint":false},{"pmid":"30597965","id":"PMC_30597965","title":"IL-6 in Osteoarthritis: Effects of Pine Stilbenoids.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30597965","citation_count":46,"is_preprint":false},{"pmid":"18473869","id":"PMC_18473869","title":"The blockade of IL-6 signaling in rational drug design.","date":"2008","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/18473869","citation_count":45,"is_preprint":false},{"pmid":"34022535","id":"PMC_34022535","title":"Therapeutic targeting of IL-6 trans-signaling.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/34022535","citation_count":42,"is_preprint":false},{"pmid":"34044328","id":"PMC_34044328","title":"Inborn errors of IL-6 family cytokine responses.","date":"2021","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34044328","citation_count":41,"is_preprint":false},{"pmid":"26204410","id":"PMC_26204410","title":"Relationship among IL-6, LDL cholesterol and lipid peroxidation.","date":"2015","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26204410","citation_count":41,"is_preprint":false},{"pmid":"33879600","id":"PMC_33879600","title":"IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33879600","citation_count":41,"is_preprint":false},{"pmid":"30342072","id":"PMC_30342072","title":"Blockade of IL-6 signaling in neuromyelitis optica.","date":"2018","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/30342072","citation_count":35,"is_preprint":false},{"pmid":"30132351","id":"PMC_30132351","title":"AA amyloidosis - Benefits and prospects of IL-6 inhibitors.","date":"2018","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/30132351","citation_count":35,"is_preprint":false},{"pmid":"31572184","id":"PMC_31572184","title":"Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31572184","citation_count":35,"is_preprint":false},{"pmid":"24859008","id":"PMC_24859008","title":"I-BET151 selectively regulates IL-6 production.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24859008","citation_count":35,"is_preprint":false},{"pmid":"24397394","id":"PMC_24397394","title":"Circulating galanin and IL-6 concentrations in gestational diabetes mellitus.","date":"2014","source":"Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24397394","citation_count":35,"is_preprint":false},{"pmid":"32546183","id":"PMC_32546183","title":"β-Catenin and TCFs/LEF signaling discordantly regulate IL-6 expression in astrocytes.","date":"2020","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/32546183","citation_count":32,"is_preprint":false},{"pmid":"15014527","id":"PMC_15014527","title":"IL-6 regulates CD44 cell surface expression on human myeloma cells.","date":"2004","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/15014527","citation_count":32,"is_preprint":false},{"pmid":"39749325","id":"PMC_39749325","title":"IL-6 and diabetic kidney disease.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39749325","citation_count":31,"is_preprint":false},{"pmid":"27863335","id":"PMC_27863335","title":"IL-6 trans-signaling is another pathway to upregulate Osteopontin.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/27863335","citation_count":31,"is_preprint":false},{"pmid":"22150003","id":"PMC_22150003","title":"Immunotherapeutic implication of IL-6 blockade.","date":"2012","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/22150003","citation_count":31,"is_preprint":false},{"pmid":"36965369","id":"PMC_36965369","title":"Inhibition of IL-6 methylation by Saikosaponin C regulates neuroinflammation to alleviate depression.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36965369","citation_count":31,"is_preprint":false},{"pmid":"31424261","id":"PMC_31424261","title":"Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib.","date":"2019","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/31424261","citation_count":30,"is_preprint":false},{"pmid":"27902467","id":"PMC_27902467","title":"Autocrine IL-6 mediates pituitary tumor senescence.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27902467","citation_count":29,"is_preprint":false},{"pmid":"14759713","id":"PMC_14759713","title":"CYP2C and IL-6 expression in breast cancer.","date":"2004","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/14759713","citation_count":29,"is_preprint":false},{"pmid":"35203527","id":"PMC_35203527","title":"Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/35203527","citation_count":29,"is_preprint":false},{"pmid":"28381401","id":"PMC_28381401","title":"Programmed cell senescence: role of IL-6 in the pituitary.","date":"2017","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28381401","citation_count":28,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45194,"output_tokens":7839,"usd":0.126583,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17472,"output_tokens":4566,"usd":0.100755,"stage2_stop_reason":"end_turn"},"total_usd":0.227338,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"IL-6 receptor system consists of two membrane proteins: a ligand-binding chain (IL-6R) and a non-ligand-binding signal transducer gp130. Binding of IL-6 to IL-6R triggers the association of IL-6R and gp130, and gp130 transduces the signal. Despite lacking IL-6 binding property, gp130 is involved in the formation of high-affinity IL-6 binding sites.\",\n      \"method\": \"Receptor binding and signal transduction studies\",\n      \"journal\": \"International journal of immunopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — foundational receptor characterization replicated across multiple labs, mechanistic framework repeatedly confirmed\",\n      \"pmids\": [\"1618596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"NF-IL6 (C/EBP homolog) is a DNA-binding protein responsible for IL-1-stimulated IL-6 induction and is identical to IL-6DBP, the DNA-binding protein responsible for IL-6-mediated induction of acute-phase proteins. NF-IL6 binds to regulatory regions of the IL-6 gene and various other inducible genes involved in acute, immune, and inflammatory responses.\",\n      \"method\": \"Direct cloning, DNA binding assay, transcription factor identification\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct cloning with functional DNA binding validation, replicated across labs\",\n      \"pmids\": [\"1380488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IL-6 type cytokine active signaling complexes with IL-6R and gp130 may exist as tetramers or hexamers; a model is proposed in which ligand-induced transition from an active tetrameric to an inactive hexameric complex serves as a molecular switch that turns off IL-6 signals at supraoptimal cytokine concentrations.\",\n      \"method\": \"Structural and biochemical analysis of receptor complex stoichiometry\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — structural/biochemical model from single lab, not independently replicated at time of publication\",\n      \"pmids\": [\"10494829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-6 transsignaling: the IL-6/soluble IL-6 receptor (sIL-6R) complex acts as an agonist by binding to gp130 on cells that do not express membrane-bound IL-6R, thereby expanding IL-6 responsiveness. This trans-signaling is a crucial mechanism in chronic inflammatory diseases including inflammatory bowel disease, peritonitis, rheumatoid arthritis, and colon cancer.\",\n      \"method\": \"In vivo mouse models, recombinant protein studies, cell signaling assays\",\n      \"journal\": \"Journal of interferon & cytokine research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple disease models and multiple labs, mechanistically defined with recombinant proteins\",\n      \"pmids\": [\"15871661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IL-6 reduces the level of apoptosis among antigen-stimulated CD4 T cells (particularly those that have undergone five or more divisions) as shown by reduced annexin V staining, without affecting proliferative rates, thereby playing a central role in determining numbers of memory/effector CD4 T cells after immunization.\",\n      \"method\": \"CFSE dilution, BrdU labeling, annexin V staining in transgenic T cell transfer model, IL-6 KO mice\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (CFSE, BrdU, annexin V) with KO controls in single lab\",\n      \"pmids\": [\"15814701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-6 promotes Th2 differentiation through activation of NFAT-mediated transcription leading to IL-4 production by naive CD4+ T cells, while simultaneously inhibiting Th1 differentiation through an IL-4- and NFAT-independent mechanism involving upregulation of SOCS-1 to interfere with IFNγ signaling.\",\n      \"method\": \"T cell differentiation assays, reporter assays, SOCS-1 expression analysis\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent molecular mechanisms identified with supporting functional assays, single lab\",\n      \"pmids\": [\"12431386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IL-6, together with TGF-β, induces differentiation of Th17 cells from naive T cells, while IL-6 also inhibits TGF-β-induced regulatory T cell (Treg) differentiation, thereby regulating the Treg/Th17 balance.\",\n      \"method\": \"T cell differentiation assays, cytokine stimulation, KO mouse models\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic finding replicated across multiple labs with defined molecular pathway\",\n      \"pmids\": [\"20583029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SOCS3 is the primary inhibitor of IL-6 signaling. Biochemical and structural studies show SOCS3 binds to gp130 and to JAK1, JAK2 and TYK2 (but not JAK3), with specificity determined by a three-residue 'GQM' motif in the kinase domain of JAK1, JAK2 and TYK2. SOCS3 binds JAK and gp130 simultaneously and inhibits JAK activity in an ATP-independent manner by partially occluding the substrate binding groove with its kinase inhibitory region.\",\n      \"method\": \"Biochemical binding assays, structural studies, mutagenesis of JAK kinase domain\",\n      \"journal\": \"Seminars in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural and biochemical data with mutagenesis defining binding specificity, mechanistically rigorous\",\n      \"pmids\": [\"24418198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Tet2 selectively mediates active repression of IL-6 transcription during inflammation resolution in innate myeloid cells. IκBζ mediates specific targeting of Tet2 to the Il6 promoter. Independent of DNA methylation and hydroxymethylation, Tet2 recruits Hdac2 and represses IL-6 transcription via histone deacetylation.\",\n      \"method\": \"Chromatin immunoprecipitation, Tet2-deficient mice, LPS challenge, gene-specific promoter analysis, histone modification assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods including ChIP, KO mice, reconstitution of repressor complex, published in high-tier journal\",\n      \"pmids\": [\"26287468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IL-6 upregulates expression of RORγt (Th17-associated transcription factor) in NK cells and promotes IL-17 production. Only a subset of NK cells expresses both chains of the IL-6R. IL-6-deficient mice challenged with T. gondii had a major defect in NK cell production of IL-17.\",\n      \"method\": \"IL-6 KO mice, T. gondii infection model, flow cytometry, RORγt expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice with defined cellular phenotype and molecular mechanism (RORγt upregulation), multiple orthogonal approaches\",\n      \"pmids\": [\"20083665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-6 activates autophagy through the IL-6/JAK2/BECN1 pathway. IL-6 triggers the interaction between JAK2 and BECN1, where JAK2 phosphorylates BECN1 at Y333. BECN1 Y333 phosphorylation is crucial for BECN1 activation and IL-6-induced autophagy by regulating PI3KC3 complex formation, and promotes chemotherapy resistance in colorectal cancer.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (Y333), autophagy flux assays, cancer cell lines and in vivo models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted kinase-substrate interaction with mutagenesis validation, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"34131122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 phosphorylation and STAT3 activation, which in turn increases RANKL expression at both mRNA and protein levels. Inhibition of JAK2 with AG490 suppressed phospho-JAK2 and RANKL expression and reduced osteoclastic differentiation.\",\n      \"method\": \"RT-PCR, Western blotting, TRAP staining, co-culture assay, JAK2 inhibitor AG490\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods including pharmacological inhibition and molecular analysis in osteocyte cell line, single lab\",\n      \"pmids\": [\"28278513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"c-Src stimulates IL-6 expression through STAT3, and IL-6 in turn induces IGFBP5 which activates c-Src, forming an amplification loop in immature osteoblasts. In mature osteoblasts this loop is broken because c-Src is downregulated. IGFBP5 produced by osteoblasts stimulates osteoclastogenesis, acting as an osteoblast-osteoclast coupling factor.\",\n      \"method\": \"In vitro and in vivo osteoblast differentiation assays, STAT3 reporter, siRNA knockdown, mouse models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling loop with in vitro and in vivo validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"22252554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In neural stem cell differentiation, IL-6 family cytokines and BMPs act synergistically to induce astrocyte differentiation. This cooperation involves formation of a complex between STAT3 (downstream of IL-6 family cytokines) and Smad1 (downstream of BMPs), bridged by the transcriptional coactivator p300. A STAT3 binding element in the GFAP promoter is regulated by DNA methylation during brain development.\",\n      \"method\": \"Transcription factor complex analysis, promoter luciferase assays, DNA methylation analysis, neuroepithelial cell culture\",\n      \"journal\": \"Clinical reviews in allergy & immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined protein complex (STAT3-Smad1-p300) with functional promoter and methylation analysis, single lab\",\n      \"pmids\": [\"16129909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Demethylase Kdm6a promotes IL-6 expression in macrophages through demethylating H3K27me3 at the IL-6 promoter in a demethylase enzymatic activity-dependent manner during innate immune responses.\",\n      \"method\": \"Chromatin immunoprecipitation, enzymatic activity-deficient mutants, primary macrophage knockdown, H3K27me3 histone modification assays\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic activity mutagenesis with ChIP demonstrating direct epigenetic mechanism at IL-6 promoter, multiple orthogonal methods\",\n      \"pmids\": [\"28284523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IL-6 stimulates intestinal epithelial proliferation and wound repair. Inhibition of IL-6 resulted in impaired wound healing due to decreased epithelial proliferation in two murine models of bowel injury (biopsy wound and bacterial-triggered colitis). IL-6 is induced after injury by multiple cell types including intraepithelial lymphocytes.\",\n      \"method\": \"Two murine bowel injury models, IL-6 inhibition, epithelial proliferation assays, human tissue analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent injury models with defined cellular phenotype (epithelial proliferation), single lab\",\n      \"pmids\": [\"25478789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Autocrine IL-6 signaling in intestinal crypt epithelium regulates crypt homeostasis through Paneth cells via pSTAT3 activation and the Wnt signaling pathway. IL-6 receptor is restricted to the basal membrane of Paneth cells. IL-6-induced crypt organoid proliferation was abrogated by the Wnt inhibitor IWP2.\",\n      \"method\": \"Mouse intestinal crypt organoids, in vivo mouse model, IL-6R blocking antibody, Wnt inhibitor IWP2, immunolabeling, IL-6 neutralizing antibody\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway defined with pathway inhibitors and both in vitro organoid and in vivo systems, multiple orthogonal methods\",\n      \"pmids\": [\"28550196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Post-myocardial infarction IL-6 is preferentially produced by cardiac fibroblasts (CFs). Adenosine stimulates fibroblast IL-6 formation via the adenosine receptor A2bR in a Gq-dependent manner. T cell-derived adenosine (from CD73 on T cells) modulates IL-6 formation in CFs, representing purinergic metabolic cooperation between CFs and T cells.\",\n      \"method\": \"Single-cell RNA-seq (mouse and human hearts), quantitative PCR, RNAscope, protein-level cell-type analysis, genetic mouse models (CD4-CD73-/-), in vitro receptor pharmacology\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — scRNA-seq confirmed in human and mouse tissue, defined receptor (A2bR/Gq) and genetic KO validation, multiple orthogonal methods\",\n      \"pmids\": [\"36943408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IL-6 functions downstream of IL-17A to exacerbate neutrophil microabscess development in psoriasiform skin lesions. IL-17A expression results in upregulated granulopoiesis and migration of IL-6R-expressing neutrophils into the skin. Neutralization of IL-6 signaling efficiently reduced epidermal neutrophil abscess formation and epidermal thickening.\",\n      \"method\": \"Transgenic IL-17A skin mouse model, IL-6 neutralization, histopathology, granulopoiesis analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis defined with transgenic model and antibody neutralization, single lab\",\n      \"pmids\": [\"24067382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-6 signaling in Tet2-deficient macrophages induces Csf1r expression through enhanced STAT3 binding to the CSF1R promoter, increasing macrophage survival and contributing to accelerated atherosclerosis in clonal hematopoiesis. IL-6 receptor antibody treatment reverses Tet2-deficient clonal hematopoiesis-promoted atherosclerosis.\",\n      \"method\": \"ChIP for STAT3 at Csf1r promoter, mouse and human Tet2-deficient macrophages, IL-6R antibody treatment, CSF1R inhibitor PLX3397, atherosclerosis mouse model\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP defines direct STAT3-mediated mechanism, validated in both mouse and human cells with pharmacological rescue, multiple orthogonal approaches\",\n      \"pmids\": [\"37539077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Phase separation of the YY1 complex in M2 macrophages upregulates IL-6 by promoting IL-6 enhancer-promoter interactions via long-range chromatin interaction. An M2-specific IL-6 enhancer was identified; YY1 formed a liquid-liquid phase separation in which p300, p65, and CEBPB acted as transcriptional cofactors to drive IL-6 expression.\",\n      \"method\": \"H3K27ac-ChIP-seq, YY1 ChIP-seq, CRISPR-Cas9 knockout, RNA-seq, liquid-liquid phase separation assays, chromatin interaction analysis\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods including ChIP-seq, LLPS assays, CRISPR KO, and long-range chromatin interaction analysis in single rigorous study\",\n      \"pmids\": [\"37094986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-6 signaling in macrophages is critical for immunotherapy-driven tumor regression. IL-6 receptor signaling in macrophages is required for effective M1-type macrophage function; IL-6 signaling blockade decreased SOCS3 expression in macrophages and increased expression of the phagocytic checkpoint molecule SIRPα. Macrophage-specific IL-6R deletion (Il6rafl/fl×LysMcre+) impaired therapy efficacy without affecting vaccine-induced CD8+ T cell responses.\",\n      \"method\": \"Macrophage-specific conditional IL-6R knockout mice, therapeutic vaccination tumor model, flow cytometry, SOCS3 and SIRPα expression analysis\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with defined molecular mechanism (SOCS3, SIRPα), multiple orthogonal methods\",\n      \"pmids\": [\"33879600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-6 upregulates CCR5 expression and arginase 1 in MDSC through a STAT3-dependent mechanism, enhancing their immunosuppressive capacity. MDSC differentiated in the presence of IL-6 strongly inhibited CD8+ T cell functions compared with MDSC differentiated without IL-6. Correlation between IL-6 levels, phosphorylated STAT3, and CCR5 expression was demonstrated in tumor-infiltrating MDSC in a transgenic melanoma model.\",\n      \"method\": \"In vitro MDSC differentiation, STAT3 phosphorylation analysis, mRNA/protein expression, RET transgenic melanoma mouse model, CD8+ T cell suppression assay\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined STAT3-dependent mechanism with in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"32788238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IL-6 treatment of myotubes increases fatty acid oxidation, basal and insulin-stimulated glucose uptake, and translocation of GLUT4 to the plasma membrane. IL-6 rapidly and markedly increases AMPK activity, and the metabolic effects of IL-6 were abrogated in AMPK dominant-negative infected cells.\",\n      \"method\": \"Myotube cell culture, fatty acid oxidation assay, glucose uptake assay, GLUT4 translocation assay, AMPK dominant-negative expression\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — AMPK dominant-negative establishes mechanistic requirement, multiple metabolic readouts, single lab\",\n      \"pmids\": [\"17956334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IL-6 inhibits allograft acceptance by promoting T cell alloimmune responses and impairing the ability of regulatory T cells to suppress effector T cell alloimmunity. Absence of both IL-6 and TNF-α in the graft recipient synergized with co-stimulatory blockade to induce tolerance.\",\n      \"method\": \"Murine skin allograft model, IL-6/TNF-α double KO, co-stimulatory blockade, in vitro and in vivo T cell assays\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO combined with transplant model defines synergistic mechanism, single lab\",\n      \"pmids\": [\"19357252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CK2 (protein kinase CK2) regulates IL-6 expression in inflammatory breast cancer. siRNA knockdown of CK2 and the selective CK2 inhibitor CX-4945 suppressed IL-6 expression and secretion in vitro and in vivo. CK2 inhibition also reduced plasma IL-6 levels in a clinical trial patient.\",\n      \"method\": \"siRNA knockdown, small molecule inhibitor (CX-4945), ELISA, in vitro and in vivo cancer models, clinical sample analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — convergent siRNA and pharmacological evidence, but single lab with limited mechanistic detail on direct vs indirect CK2 action\",\n      \"pmids\": [\"22027148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The BET bromodomain protein inhibitor I-BET151 selectively inhibits IL-6 production (but not TNFα, IL-1β, or IL-10) in LPS-stimulated macrophages by preventing the binding of CBP to the IL-6 promoter, without affecting NF-κB acetylation, phosphorylation, nuclear translocation, or DNA binding.\",\n      \"method\": \"Chromatin immunoprecipitation (CBP binding at IL-6 promoter), cytokine ELISA, NF-κB activity assays, LPS-stimulated RAW264.7 cells\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP defines direct CBP recruitment mechanism with selectivity demonstrated by parallel cytokine measurements, single lab\",\n      \"pmids\": [\"24859008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-6 trans-signaling via soluble IL-6R drives crescentic nephritis. Specific inhibition of IL-6 trans-signaling using recombinant sgp130Fc resulted in milder nephritis, while specific activation using a recombinant IL-6-sIL-6R fusion molecule (Hyper-IL-6) significantly aggravated disease and increased systolic BP. Simultaneous inhibition of both IL-6 signaling pathways using anti-IL-6 antibody alone had no significant impact.\",\n      \"method\": \"Nephrotoxic serum-induced nephritis mouse model, recombinant sgp130Fc (trans-signaling specific inhibitor), Hyper-IL-6 fusion protein, pSTAT3/SOCS3 analysis, Th17 cytokine measurement\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway-specific inhibition and activation with recombinant proteins establishes trans-signaling mechanism, multiple readouts, single lab\",\n      \"pmids\": [\"26041841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Autocrine IL-6 maintains cellular senescence in pituitary somatotroph tumor cells. Endogenous IL-6 inhibition via shRNA in MtT/S clones decreased SA-β-gal activity and p16INK4a but increased pRb and proliferation/invasion. IL-6-silenced clones became tumorigenic in nude mice, while wild-type MtT/S cells did not, demonstrating that escape from IL-6-driven senescence enables malignant transformation.\",\n      \"method\": \"shRNA stable knockdown, SA-β-gal staining, p16INK4a/pRb Western blot, nude mouse xenograft, human pituitary tumor samples\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA KD with in vitro and in vivo phenotypic validation including senescence markers, single lab\",\n      \"pmids\": [\"27902467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In human astrocytes, β-catenin in complex with TCF/LEF inhibits IL-6 transcription, while TCF/LEF independent of β-catenin induces IL-6 transcription through interaction with ATF-2/SMADs. β-catenin independent of TCFs/LEF positively regulates C/EBP and NF-κB to activate IL-6 expression. Two TCF/LEF binding sites in the IL-6 promoter were identified (at -91 nt and -948 nt from TSS), both required for TCF/LEF induction of IL-6.\",\n      \"method\": \"siRNA knockdown, cDNA overexpression, IL-6 promoter luciferase reporter, site-directed mutagenesis of promoter sites, chromatin immunoprecipitation, pharmacological agents\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis and ChIP define binding sites, multiple complementary approaches, single lab\",\n      \"pmids\": [\"32546183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-6 strongly increases CD44 gene expression in multiple myeloma cells, modulates CD44 RNA alternative splicing inducing overexpression of all CD44 variant exons, and induces a functional polarized membrane distribution of CD44 cell surface molecules.\",\n      \"method\": \"RT-PCR, Western blot, flow cytometry, cell surface distribution analysis in myeloma cell lines\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple molecular readouts (mRNA splicing, protein expression, surface distribution) in cell lines, single lab\",\n      \"pmids\": [\"15014527\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-6 is a pleiotropic cytokine that signals through a receptor complex comprising IL-6R and gp130: binding of IL-6 to IL-6R triggers association with gp130, which dimerizes and initiates intracellular JAK-STAT3, Ras-MAPK, and PI3K-Akt signaling; trans-signaling extends this response to cells lacking membrane IL-6R by using soluble IL-6R complexed with gp130; SOCS3 terminates signaling by simultaneously binding gp130 and JAK1/2/TYK2 to occlude the kinase substrate groove; at the transcriptional level, IL-6 gene expression is regulated by NF-IL6/C/EBP, NF-κB, STAT3, and epigenetic mechanisms including Tet2-Hdac2-mediated histone deacetylation for resolution-phase repression, Kdm6a-mediated H3K27 demethylation for induction, and YY1 phase-separation complexes at enhancers; downstream, IL-6 controls immune cell fate (Th17/Treg balance, CD4 T cell survival, NK cell IL-17 production), metabolic responses (AMPK activation, GLUT4 translocation), cellular senescence (autocrine loop in pituitary adenomas), autophagy (via JAK2 phosphorylation of BECN1 at Y333), and tissue homeostasis (intestinal crypt Paneth cell-Wnt axis), with post-MI IL-6 production being predominantly driven by cardiac fibroblasts via adenosine/A2bR/Gq signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IL-6 is a pleiotropic secreted cytokine that orchestrates immune cell fate, tissue repair, and metabolic responses by signaling through a two-chain receptor system in which a ligand-binding chain (IL-6R) captures IL-6 and triggers association with the signal-transducing chain gp130, the latter forming high-affinity binding sites and transducing the intracellular signal [#0]. The active signaling complex assembles into higher-order tetrameric/hexameric stoichiometries, and a ligand-induced transition to an inactive hexamer can act as a switch that limits signaling at supraoptimal cytokine concentrations [#2]. IL-6 also acts via trans-signaling, in which the IL-6/soluble IL-6R complex agonizes gp130 on cells lacking membrane IL-6R, a mechanism that drives chronic inflammatory disease including bowel inflammation, rheumatoid arthritis, and crescentic nephritis [#3, #27]. Downstream, IL-6 engages a JAK2-STAT3 axis that phosphorylates STAT3 to control target gene transcription — driving RANKL for osteoclastogenesis [#11], CSF1R for macrophage survival [#19], and immunosuppressive programs (CCR5/arginase-1) in MDSC [#22] — and JAK2 also phosphorylates BECN1 at Y333 to activate PI3KC3-dependent autophagy [#10]. The cytokine is a central determinant of T cell fate, cooperating with TGF-\\u03b2 to induce Th17 differentiation while suppressing Treg differentiation [#6], reducing apoptosis of antigen-stimulated CD4 T cells [#4], and inducing IL-17 production in NK cells via ROR\\u03b3t [#9]. Beyond immunity, IL-6 promotes intestinal epithelial proliferation and crypt homeostasis through a Paneth cell pSTAT3-Wnt axis [#16], activates AMPK to stimulate fatty acid oxidation and GLUT4-mediated glucose uptake in muscle [#23], and sustains autocrine senescence in pituitary tumor cells [#28]. Signaling is terminated by SOCS3, which binds gp130 and JAK1/JAK2/TYK2 simultaneously (via a GQM motif in the kinase domain) and occludes the substrate groove in an ATP-independent manner [#7]. IL-6 transcription itself is tightly controlled by transcription factors NF-IL6/C/EBP, NF-\\u03baB, and STAT3 together with epigenetic machinery, including Tet2-Hdac2-mediated histone deacetylation for resolution-phase repression [#8], Kdm6a-mediated H3K27 demethylation for induction [#14], and YY1 phase-separation enhancer complexes [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established the architecture of IL-6 reception by resolving that ligand binding and signal transduction are split between two membrane chains, defining how IL-6 can be sensed and propagated.\",\n      \"evidence\": \"Receptor binding and signal transduction studies of IL-6R and gp130\",\n      \"pmids\": [\"1618596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the active complex not resolved here\", \"Intracellular effectors of gp130 not yet defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Identified NF-IL6/C/EBP as the DNA-binding factor coupling inflammatory stimuli to IL-6 gene induction, linking IL-6 transcription to the acute-phase response.\",\n      \"evidence\": \"Direct cloning and DNA-binding assays identifying NF-IL6 at IL-6 regulatory regions\",\n      \"pmids\": [\"1380488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Combinatorial control with other factors not defined\", \"No chromatin-level mechanism established\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Proposed that receptor complex stoichiometry (tetramer-to-hexamer transition) functions as a built-in molecular switch limiting signaling at high ligand, addressing how IL-6 responses are self-limited.\",\n      \"evidence\": \"Structural and biochemical analysis of IL-6/IL-6R/gp130 complex stoichiometry\",\n      \"pmids\": [\"10494829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab structural model not independently replicated at publication\", \"Physiological relevance of the switch in vivo unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined IL-6 trans-signaling, showing the soluble IL-6R/IL-6 complex extends responsiveness to gp130-bearing cells lacking IL-6R, explaining IL-6's role in chronic inflammation.\",\n      \"evidence\": \"In vivo mouse disease models and recombinant protein signaling assays\",\n      \"pmids\": [\"15871661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular source of sIL-6R per tissue not fully mapped\", \"Relative contribution of classic vs trans-signaling per disease unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed IL-6 shapes adaptive immunity by reducing apoptosis of divided antigen-stimulated CD4 T cells, establishing its role in memory/effector T cell accumulation.\",\n      \"evidence\": \"CFSE/BrdU/annexin V assays in transgenic T cell transfer and IL-6 KO mice\",\n      \"pmids\": [\"15814701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream survival effectors not identified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed IL-6 at the center of the Treg/Th17 decision, demonstrating it cooperates with TGF-\\u03b2 to drive Th17 while blocking Treg differentiation, and extends Th17-like programs to NK cells.\",\n      \"evidence\": \"T cell differentiation assays and KO mice; ROR\\u03b3t analysis in NK cells in T. gondii infection\",\n      \"pmids\": [\"20583029\", \"20083665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional logic of the Treg/Th17 switch not fully detailed\", \"NK IL-6R expression heterogeneity not explained\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved the structural basis of IL-6 signal termination, showing SOCS3 simultaneously engages gp130 and specific JAKs to occlude the kinase substrate groove.\",\n      \"evidence\": \"Biochemical binding, structural studies, and mutagenesis of the JAK GQM motif\",\n      \"pmids\": [\"24418198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics of SOCS3 induction vs signaling not quantified\", \"JAK3 exclusion mechanism beyond GQM not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected IL-6 gene control to active epigenetic repression, showing Tet2 (targeted by I\\u03baB\\u03b6) recruits Hdac2 to deacetylate the Il6 promoter independently of DNA methylation during inflammation resolution.\",\n      \"evidence\": \"ChIP, Tet2-deficient mice, LPS challenge, histone modification assays\",\n      \"pmids\": [\"26287468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals triggering resolution-phase Tet2 recruitment not fully defined\", \"Generalizability beyond myeloid cells unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified the opposing inductive epigenetic arm, with Kdm6a demethylating H3K27me3 at the IL-6 promoter to permit expression during innate responses.\",\n      \"evidence\": \"ChIP, enzymatic-dead mutants, and primary macrophage knockdown\",\n      \"pmids\": [\"28284523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals recruiting Kdm6a not defined\", \"Interplay with Tet2-Hdac2 repression not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked IL-6/JAK2/STAT3 signaling to bone remodeling, showing it raises RANKL to enhance osteocyte-mediated osteoclastogenesis.\",\n      \"evidence\": \"RT-PCR, Western blot, TRAP staining, co-culture, and JAK2 inhibition (AG490)\",\n      \"pmids\": [\"28278513\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect STAT3 control of RANKL promoter not resolved\", \"Single cell-line system\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded IL-6's intracellular reach to autophagy, demonstrating JAK2 phosphorylates BECN1 at Y333 to drive PI3KC3 complex formation and chemoresistance.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, Y333 mutagenesis, autophagy flux, and cancer models\",\n      \"pmids\": [\"34131122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-proximal coupling to cytosolic JAK2-BECN1 not fully mapped\", \"Generalizability beyond colorectal cancer unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed IL-6 metabolically reprograms muscle, rapidly activating AMPK to drive fatty acid oxidation and GLUT4-dependent glucose uptake.\",\n      \"evidence\": \"Myotube metabolic assays with AMPK dominant-negative expression\",\n      \"pmids\": [\"17956334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor route (classic vs trans) in myotubes not specified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the cellular source and induction of IL-6 in injured heart, showing cardiac fibroblasts produce IL-6 via adenosine/A2bR/Gq signaling fed by T cell-derived adenosine.\",\n      \"evidence\": \"scRNA-seq (mouse and human), RNAscope, CD4-CD73 KO mice, receptor pharmacology\",\n      \"pmids\": [\"36943408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream cardiac consequences of fibroblast IL-6 not detailed here\", \"Translation to human cardiac outcomes pending\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed enhancer-level control of IL-6 in tumor-associated macrophages, with YY1 liquid-liquid phase separation organizing p300/p65/CEBPB to drive M2-specific enhancer-promoter looping.\",\n      \"evidence\": \"H3K27ac/YY1 ChIP-seq, CRISPR KO, LLPS assays, chromatin interaction analysis\",\n      \"pmids\": [\"37094986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Triggers of YY1 condensate formation not defined\", \"Relationship to NF-IL6/STAT3 promoter control unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the receptor-proximal JAK-STAT3 module is integrated with the diverse downstream effectors (autophagy, AMPK metabolism, senescence) and the multilayered transcriptional/epigenetic control of the IL-6 gene into a unified, context-dependent response remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No single framework reconciles classic vs trans-signaling outputs across tissues\", \"Quantitative integration of activating (Kdm6a, YY1) and repressive (Tet2-Hdac2) IL-6 transcription not established\", \"Structural basis of the proposed hexamer off-switch in vivo not confirmed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 6, 9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 14, 20]}\n    ],\n    \"complexes\": [\"IL-6/IL-6R/gp130 signaling complex\"],\n    \"partners\": [\"IL6R\", \"IL6ST\", \"SOCS3\", \"JAK2\", \"STAT3\", \"BECN1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}